BOULDER, Colo.--(BUSINESS WIRE)--Jan. 4, 2012--
Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief
Executive Officer, Robert E. Conway, will speak at the 30th
Annual J.P. Morgan Healthcare Conference in San Francisco. The public is
welcome to participate in the conference through a webcast on the Array
BioPharma website.
|
Event:
|
|
|
30th Annual J.P. Morgan Healthcare Conference
|
|
Presenter:
|
|
|
Robert E. Conway, Chief Executive Officer, Array BioPharma
|
|
Date:
|
|
|
Wednesday, January 11, 2012
|
|
Time:
|
|
|
3:00 p.m. Pacific Time
|
|
Location:
|
|
|
Westin St. Francis Hotel, San Francisco
|
|
Webcast:
|
|
|
www.arraybiopharma.com
|
About Array BioPharma
Array BioPharma Inc. is a biopharmaceutical company focused on the
discovery, development and commercialization of targeted small-molecule
drugs to treat patients afflicted with cancer and inflammatory diseases.
Array has four core proprietary clinical programs: ARRY-614 for
myelodysplastic syndromes, ARRY-520 for multiple myeloma, ARRY-797 for
pain and ARRY-502 for asthma. In addition, Array has 10 partner-funded
clinical programs including two MEK inhibitors in Phase 2: selumetinib
with AstraZeneca and MEK162 with Novartis. For more information on
Array, please go to www.arraybiopharma.com.
Source: Array BioPharma Inc.
Array BioPharma Inc.
Tricia Haugeto, 303-386-1193
thaugeto@arraybiopharma.com
